Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Primary Biliary Cholangitis - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides ...

DelveInsight’s Primary Biliary Cholangitis Market Insights report includes a comprehensive understanding of current treatment practices, primary biliary cholangitis emerging drugs, market share of ...

Results from the GLISTEN study, the largest investigational trial of pruritus in primary biliary cholangitis (PBC), indicate ...

Seladelpar is an oral, selective peroxisome proliferator-activated receptor delta agonist. Treatment with seladelpar was associated with an improvement in cholestatis markers in patients with primary ...

The cholangitis infection is often caused by bacteria, a gallstone or any another blockage. Primary biliary cholangitis is a chronic condition where inflammation of the bile duct system keeps bile ...

Distinct lipid changes in primary biliary cholangitis may signal inflammation and fibrosis. Discover how these findings could ...

—A recent study provides genetic evidence linking a higher body mass index (BMI) to an increased risk of primary biliary cholangitis and autoimmune hepatitis but a decreased risk of primary sclerosing ...

Large PBC cohort shows current liver stiffness measurement >10 kPa predicts hepatic decompensation, outperforming biochemical response or LSM trajectory. Learn more ...

While PBC progresses slowly and many patients do not experience symptoms during the early stages of disease, there are many symptoms to look out for. In later stages of disease, patients may ...

The treatment is expected to reprogram the immune system to induce tolerance to PDC-E2. The Food and Drug Administration (FDA) has granted Fast Track designation to CNP-104 for the treatment of ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of two per 100,000 people per year and an estimated prevalence of 15 per ...

AMSTERDAM — Patients with an incomplete response to first-line therapy for primary biliary cholangitis are significantly more likely to achieve a complete biochemical response with bezafibrate ...